MiMedx (MDXG) Q3 2026 Earnings Call Transcript
MiMedx (MDXG) reported Q3 2026 net sales of $62M, with Surgical revenue up 9% YoY and Wound Care Center volume up 7% sequentially. The company expects to complete the Sanara MedTech acquisition, pending FTC approval, aiming for $400M in combined revenue and 20% adjusted EBITDA margin. MiMedx also won a court ruling against the FDA's classification of AXIOFILL and reached a $25M settlement in a patent infringement case.
How this was made

The 30-second read
Why it matters
The settlement removes a legal headwind and adds cash, while the FTC second request introduces uncertainty for the pending Sanara acquisition.
Market read
Provides fresh earnings data, settlement details, and acquisition status that can influence MDXG trading decisions.
What to watch
Potential integration challenges and reimbursement policy changes for wound‑care products.
Background
MiMedx reported Q3 2026 financials, highlighted surgical revenue growth, wound‑care challenges, and a $25M settlement with a patent infringer.
Ticker impact
MiMedx disclosed Q3 results, a $25M settlement, and progress on the Sanara acquisition pending FTC review.
potential modest upside from settlement and growth, offset by possible downside from regulatory delay
Settlement adds cash and removes litigation risk; acquisition progress is positive, but FTC scrutiny introduces uncertainty.
Market effects
Surgical and wound‑care biotech sector may see increased interest in M&A activity.
U.S. biotech investors may adjust positions in regenerative‑medicine stocks.
Limited to U.S. biotech and healthcare investors.
Counterpoint
Regulatory delay could stall the deal, leading to a sell‑off despite short‑term settlement boost.
Key entities
- CompanyMiMedx Group Inc.
Regenerative medicine company reporting Q3 results.
- CompanySanara MedTech
Target of MiMi's pending acquisition.


